Please rate this video!

VJVirtual | CLL outcomes after CD19 CAR-T with ibrutinib

Please rate this video!

Jordan Gauthier

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discussed the clinical outcomes of patients with chronic lymphocytic leukemia (CLL) with relapsed or refractory disease after CD19-specific CAR-T therapy used concurrently with ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter